A QSP model of prostate cancer immunotherapy to identify effective combination therapies

Area of Science:

• Computational biology and immunology
• Quantitative Systems Pharmacology (QSP) modeling
• Cancer immunotherapy research

Background:

• Immunotherapy shows promise for various cancers but is less effective for advanced castration-resistant prostate cancer.
• Novel therapeutic strategies are needed to improve outcomes for patients with refractory prostate cancer.
• Systems pharmacology modeling offers a quantitative approach for in silico evaluation of novel cancer treatments.

Purpose of the Study:

• To develop and present a novel Quantitative Systems Pharmacology (QSP) model for prostate cancer immunotherapy.
• To evaluate the efficacy of various combination immunotherapies in silico using the developed QSP model.
• To identify optimal combination strategies for advanced, treatment-resistant prostate cancer.

Main Methods:

• Developed a QSP model using Ordinary Differential Equations (ODEs) to simulate tumor dynamics and immune responses.
• Calibrated the model using pre-clinical data from prostate cancer mouse models.
• Evaluated numerous combination therapies, assessing tumor inhibition and synergistic effects via a decision tree.

Main Results:

• Simulations identified cancer vaccine combined with immune checkpoint blockade as the most effective dual-drug immunotherapy.
• This combination demonstrated significant potential for patients resistant to androgen-deprivation therapy.
• The model successfully integrated tumor, immune, and treatment components for comprehensive analysis.

Conclusions:

• The developed QSP model serves as a valuable computational framework for advancing prostate cancer immunotherapy research.
• It aids in generating testable hypotheses for pre-clinical experimental validation.
• This approach supports rational drug development and optimization of combination immunotherapies.